Global Real-Time PCR (qPCR) Market Overview
The Real-Time PCR (qPCR) Market Size was valued at USD 5.99 billion in 2023 and is projected to grow from USD 6.52 Billion in 2024 to USD 10.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00% during the forecast period (2024-2032).Real-time PCR is in greater demand because of the COVID-19 pandemic, the rising incidence of the illnesses it detects, and advances in qPCR technology. These are just a few market drivers driving the Real-Time PCR (qPCR) market.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Real-Time PCR (qPCR) Market Trends
- Rising Incidence of Genetic Disorders & Life-Threatening Infectious Diseases will boost the market growth
The major factors propelling the growth of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market during the forecast period include the increasing prevalence of genetic disorders, target infectious disease, increasing use of biomarker profiling for disease diagnostics, and the completion of the Human Genome Project successfully. The need for Digital PCR (dPCR) is anticipated to rise in the next years due to rising technological breakthroughs in PCR technologies, as well as rising investments, funding, and grants. Growth in the prevalence of target diseases around the world coupled with the proven effectiveness of clinical diagnostic tests like Digital PCR (dPCR) and Real-time PCR (qPCR) Market analysis in the diagnosis and valuation of disease-causing microbes will drive the use of these tests, which are anticipated to help the Market grow throughout the forecast period. During the forecast period, the Real-Time PCR (qPCR) market is expected to grow at a faster rate due to increasing market penetration in emerging nations and a shift in consumer perception from plant-delivered drugs to genome-based drugs. Additionally, the shift from plant-based to genome-based drug discovery would provide room for the Market for digital PCR (dPCR) and Real-time PCR (qPCR) to expand in the future. Additionally, it is anticipated that during the projection period, the expansion of the Digital PCR (dPCR) and Real-time PCR (qPCR) Market will be constrained by PCR's technological constraints and the rising cost of PCR instruments. Thus, this factor is driving the market CAGR.
For instance, the SARS-CoV-2 ddPCR Kit from Bio-Rad received Emergency Use Authorization (EUA) from the U.S. FDA in September 2020 to be used in the detection of SARS-CoV-2 infection. To lessen the effects of the COVID-19 epidemic, regulatory bodies have also stated their strong support for the approval of these tests. Further, the significance of qPCR and dPCR technologies in genomics research is emphasized by governments and federal bodies throughout the globe. Additionally, during the past ten years, the qPCR and dPCR sectors have experienced financial initiatives from governmental and business entities to support genomic research. Thus, this aspect will accelerate Real-Time PCR (qPCR) market revenue globally.
Real-Time PCR (qPCR) Market Segment Insights
Real-Time PCR (qPCR) Product Insights
The Real-Time PCR (qPCR) market segmentation, based on Product, includes Reagents & Consumables, Instruments, Software & Services. The arabica segment held the majority share in 2022 in the Real-Time PCR (qPCR) market data. The Market for qPCR reagents and consumables is anticipated to grow as a result of factors such as the expanding applications of qPCR (due to its technological advantages over traditional PCR, such as real-time analysis and reduced analysis time), increasing private-public funding for life science research, and the rise in probe-based multiplex genetic analysis procedures (which call for the analysis of low-volume gene samples).
Real-Time PCR (qPCR) Application Insights
Based on application, the Real-Time PCR (qPCR) market segmentation includes Clinical, Research, and Forensics. The Clinical segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Spectroscopy and liquid chromatography, two cutting-edge molecular diagnostic methods, are being linked with qPCR procedures to provide genomic lab staff the capacity to quickly and accurately identify pathogens. In order to identify antibiotic resistance and gene mutation in the target microorganisms, qPCR has an advantage over other conventional diagnostic methods including immunological testing, biochemical tests, and serological examination of the sample.
Figure 1: Real-Time PCR (qPCR) Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Real-Time PCR (qPCR) End-user Insights
The Real-Time PCR (qPCR) market data, based on End-user, & includes Hospitals' Diagnostic Centers, Research Laboratories & Academic Institutes, Pharmaceutical & Biotechnology Companies, Clinical Research Organizations, and Forensic Laboratories. The Hospitals Diagnostic Centers segment dominated the Real-Time PCR (qPCR) market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This can be attributed to the rising demand for early and effective disease diagnosis, and treatment, the rise in the number of dPCR Product launches for diagnostic uses, the advantages of dPCR in disease diagnosis (as compared to other PCR technologies), and the rising level of public awareness of these advantages.
Real-Time PCR (qPCR) Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Real-Time PCR (qPCR) market accounted for USD 2.519 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Because of the region's high illness prevalence, favorable rules, and several government-sponsored programs to expand the healthcare infrastructure. Additionally, the substantial presence of well-known manufacturers in the area and the rising need for quick diagnostic tests would be key drivers of the North American Real-Time PCR (qPCR) market throughout the projected period.
Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: REAL-TIME PCR (QPCR) MARKET SHARE BY REGION 2023 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Asia-Pacific Real-Time PCR (qPCR) Market is anticipated to develop at the fastest CAGR from 2023 to 2030. Due to major advancements in PCR technology made by China and Japan, as well as the growth of healthcare, R&D, and clinical research frameworks by growing nations like India and Australia, the Asia Pacific region is the most profitable Real-Time PCR (qPCR) market. Throughout the anticipated time frame, the Market will have profitable growth prospects. Further, the China Real-Time PCR (qPCR) Market held the largest market share, and the India Real-Time PCR (qPCR) Market was the fastest growing Market in the region.
Europe's Real-Time PCR (qPCR) market accounts for the third-largest market share Real-Time PCR (qPCR) techniques supported by the government and rising demand for Real-Time PCR testing to combat infectious illnesses like COVID-19 are driving the real-time PCR market in Europe. Additionally, the frequency of viral and genetic illnesses, the need for quick diagnoses, and quick technology improvements are all contributing to the real-time PCR (qPCR) Market's expansion. Moreover, U.K. Real-Time PCR (qPCR) Market held the largest market share, and the Germany Real-Time PCR (qPCR) Market was the fastest-growing Market in the region.
Real-Time PCR (qPCR) Key Market Players & Competitive Insights
Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for Real-Time PCR (qPCR). With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming increasingly competitive, Real-Time PCR (qPCR) industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business methods used by producers in the Real-Time PCR (qPCR) industry to benefit customers and increase the market sector. The Real-Time PCR (qPCR) industry has recently given medicine some of the most important advantages. The Real-Time PCR (qPCR) Market major players such as ABL SA Group (Luxembourg), Agilent Technologies Inc. (U.S.), Analytik Jena AG (Germany), B.D. (U.S.), Bio-Rad LaboratoriesInc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Fluidigm Corporation (U.S.), Lumex Instruments (U.S.), Primerdesign Ltd (U.K.), QIAGEN (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific (U.S.), TOYOBO Inc. (Japan), Vela Diagnostics (Singapore) Company.
The California-based life science startup Azure Biosystems is committed to advancing knowledge in uncharted territories. The Azure Cielo Real-time PCR device was introduced by Azure Biosystems (U.S.) in June 2020. This 96-well qPCR machine offers a high level of performance, a small footprint, and an easy workflow. The genomics workflow has been given priority in the sensitivity and reproducibility of the Azure Biosystem.
American medical device and healthcare corporation Abbott Laboratories is headquartered in Abbott Park, Illinois. The m2000 RealTime SARS-CoV-2 EUA test, which runs its operations on the m2000 RealTime System situated in hospitals and reference laboratories worldwide, was introduced by the Abbott (U.S.) corporation in March 2020. Every month, the company hopes to produce 5 million tests.
Key Companies in the Real-Time PCR (qPCR) market include
- ABL SA Group (Luxembourg)
- Agilent Technologies Inc. (U.S.)
- Analytik Jena AG (Germany)
- B.D. (U.S.)
- Bio-Rad LaboratoriesInc. (US
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fluidigm Corporation (U.S.)
- Lumex Instruments (U.S.)
- Primerdesign Ltd (UK)
- QIAGEN (Germany)
- Takara Bio Inc. (Japan)
- Thermo Fisher Scientific (U.S.)
- TOYOBO Inc. (Japan)
Real-Time PCR (qPCR) Industry Developments
February 2022:The COVID-19 PCR tests were expanded by F. Hoffmann-La Roche Ltd. in nations that accepted the C.E. market. It is projected that company expansion will boost its market share.
May 2020:The SARS-CoV-2 multiplex real-time PCR test was given emergency use permission (EUA) by the US FDA to Thermo Fisher Scientific, Inc.
September 2020:Roche Diagnostics gave the cobas BKV test US FDA 510k approval.
May 2020:Abbott Laboratories was approved by the US FDA for a SARS-CoV-2 ass.
Real-Time PCR (qPCR) Market Segmentation
Real-Time PCR (qPCR) Product Outlook (USD billion, 2018-2030)
Real-Time PCR (qPCR) Application Outlook (USD billion, 2018-2030)
Real-Time PCR (qPCR) End-User Outlook (USD billion, 2018-2030)
-
Hospitals &Diagnostic Centers
-
Research Laboratories & Academic Institutes
-
Pharmaceutical & Biotechnology Companies
-
Clinical Research Organizations
-
Forensic Laboratories
Real-Time PCR (qPCR) Regional Outlook (USD Billion, 2018-2030)
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2023 |
USD 5.99 billion |
| Market Size 2024 |
USD 6.52 billion |
| Market Size 2032 |
USD 10.8 billion |
| Compound Annual Growth Rate (CAGR) |
5.00% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2018 - 2021 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product, Application, End user and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S, Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
ABL SA Group (Luxembourg), Agilent Technologies Inc. (U.S.), Analytik Jena AG (Germany), B.D. (U.S.), Bio-Rad LaboratoriesInc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Fluidigm Corporation (U.S.), Lumex Instruments (U.S.), Primerdesign Ltd (U.K.), QIAGEN (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific (U.S.), TOYOBO Inc. (Japan), Vela Diagnostics (Singapore) Company |
| Key Market Opportunities |
Increasing adoption of real-time PCR kits to overcome the pandemic situation |
| Key Market Dynamics |
Rising demand for Real-time PCR amid the COVID-19 pandemic Increasing prevalence of target diseases and technological advancements in qPCR |
Real-Time PCR qPCR Market Highlights:
Frequently Asked Questions (FAQ) :
The Real-Time PCR (qPCR) market size was valued at USD 5.99 Billion in 2023.
The Real-Time PCR (qPCR) market is projected to grow at a CAGR of 5.00% during the forecast period 2024-2032.
North America had the largest real-time PCR (qPCR)market share.
The key players in the Real-Time PCR (qPCR) market are ABL SA Group (Luxembourg), Agilent Technologies Inc. (U.S.), Analytik Jena AG (Germany), and B.D. (U.S.), Bio-Rad LaboratoriesInc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Fluidigm Corporation (U.S.), Lumex Instruments (U.S.), Primerdesign Ltd (U.K.), QIAGEN (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific (U.S.), TOYOBO Inc. (Japan), Vela Diagnostics (Singapore) Company.
The reagent and consumables category dominated the Real-Time PCR (qPCR)market in 2022.
The clinical had the largest market share in the Real-Time PCR (qPCR).
